Core Viewpoint - A securities fraud class action lawsuit has been filed against Richtech Robotics Inc. (RR) on behalf of investors who acquired its securities between January 27, 2026, and January 29, 2026, following misleading statements regarding a collaboration with Microsoft [1] Group 1: Company Overview - Richtech Robotics Inc. announced a collaboration with Microsoft's AI Co-Innovation Labs on January 27, 2026, which led to a 44.6% increase in its stock price [1] - On January 29, 2026, Hunterbrook Media reported that the collaboration was merely a "standard" customer program with "no commercial element," resulting in a stock price drop of $1.06, or 20.9%, closing at $4.02 per share [1] Group 2: Lawsuit Details - The lawsuit alleges that Richtech made materially false and misleading statements and failed to disclose adverse facts about its business and prospects [1] - Specifically, it is claimed that Richtech misrepresented its relationship with Microsoft, leading to misleading positive statements about the company's operations [1]

Core Viewpoint - Paysafe Limited (PSFE) is facing a class action lawsuit due to alleged securities fraud, following a significant drop in its stock price after disappointing financial results were announced [1] Financial Performance - For Q3 2025, Paysafe reported revenue of $433.8 million, missing consensus estimates by $5.8 million - The company experienced a net loss of $87.7 million, a substantial increase from a net loss of $12.98 million in the same period the previous year - Full year 2025 expected revenue was revised down to $17 million at the midpoint, with adjusted EPS projected at $0.50 [1] Issues Leading to Lawsuit - The lawsuit alleges that Paysafe's ecommerce business had significant exposure to a single high-risk client, leading to understated credit loss reserves and write-offs - The company faced undisclosed issues with higher risk Merchant Category Codes, complicating its banking relationships - These factors were likely to negatively impact revenue growth and overall revenue mix, making it unlikely for Paysafe to meet its previously issued financial guidance for fiscal year 2025 [1] Stock Market Reaction - Following the announcement of the financial results, Paysafe's stock price fell by $2.80, or 27.6%, closing at $7.36 per share on November 13, 2025, with unusually high trading volume [1]

Core Viewpoint - A class action lawsuit has been filed against Paysafe Limited and certain officers for alleged violations of federal securities laws during the class period from March 4, 2025, to November 12, 2025, seeking to recover damages for affected investors [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that Paysafe failed to disclose issues related to higher risk Merchant Category Codes, which complicated its client services and banking [3] - It is claimed that these undisclosed issues would likely have a material negative impact on the company's revenue growth and overall revenue mix [3] - The lawsuit asserts that Paysafe was unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [3] - Defendants' positive statements regarding the company's business and prospects were allegedly materially misleading and lacked a reasonable basis [3] Next Steps for Investors - Investors who suffered losses in Paysafe have until April 7, 2026, to request appointment as lead plaintiff in the class action [4] - Participation in any recovery does not require serving as lead plaintiff [4] Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5] - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6]

Core Viewpoint - A class action lawsuit has been filed against Masonite International Corporation and certain officers for alleged violations of federal securities laws during the specified class period from June 5, 2023, to February 8, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Masonite securities during the class period [2]. - The complaint alleges that Masonite received multiple formal acquisition offers from Owens Corning at prices significantly above the market prices but failed to disclose this information [3]. - It is claimed that Masonite continued to repurchase its common stock from investors at prices below the acquisition offer levels, which misled investors regarding the company's operations and stock repurchase activities [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Masonite have until April 7, 2026, to request to be appointed as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6]. - The firm emphasizes restoring investor capital and ensuring corporate accountability to maintain market integrity [6].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking to recover damages for affected investors [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Inovio and its officers made materially false and misleading statements regarding the company's business and operations throughout the Class Period [3]. - Specific allegations include that Inovio lacked sufficient information to justify the eligibility of the INO-3107 Biologics License Application (BLA) for FDA accelerated approval or priority review [3][8]. - Additional claims state that manufacturing for Inovio's CELLECTRA device was deficient, and thus, the submission of the INO-3107 BLA to the FDA by the second half of 2024 was unlikely [8]. Group 2: Investor Participation - Investors who purchased Inovio securities during the Class Period are encouraged to join the lawsuit, with a deadline to request lead plaintiff status by April 7, 2026 [2][3]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only recover costs if the lawsuit is successful [4]. Group 3: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [5]. - The firm's mission focuses on restoring investor capital and ensuring corporate accountability to maintain market integrity [5].

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Oracle Corporation (“Oracle” or the “Company”) (NYSE: ORCL) between June 12, 2025 and December 16, 2025, inclusive. Should You Join The Oracle Class Action Lawsuit: Do you, or did you, own shares of Oracle Corporation (OWL)?Did you purchase your shares between June 12, 2025 and December 1 ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against BlackRock TCP Capital Corp. for alleged misrepresentations regarding the valuation of the Company's investments during a specified period [1][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired BlackRock securities between November 6, 2024, and January 23, 2026 [1]. - Defendants are accused of making misrepresentations concerning the valuation of the Company's investments [4]. Group 2: Legal Process - Investors wishing to serve as lead plaintiff must file papers by April 6, 2026, and can still share in any recovery without being the lead plaintiff [3]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders pay no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its inception in 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions [5].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) for allegedly concealing a significant increase in loan delinquencies during a specific period, leading to investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit represents investors who acquired Sallie Mae securities from July 25, 2025, to August 14, 2025 [1][2]. - The complaint claims that Sallie Mae misled investors about the nature of rising early-stage delinquencies, attributing them to seasonal trends while downplaying the effectiveness of their loss mitigation programs [3]. Group 2: Financial Impact - A TD Cowen report revealed that July delinquencies increased by 49 basis points month-over-month, which was higher than expected for that season [4]. - Following the report, Sallie Mae's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified class period, alleging misleading statements regarding clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Ultragenyx shares from August 3, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations - The complaint claims that Ultragenyx misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Ultragenyx's share price fell from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, representing a decline of over 42% in a single day [3]. Group 3: Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, focusing on treatments for rare diseases [2].

Core Viewpoint - A class action lawsuit has been filed against Coupang, Inc. for allegedly misleading investors regarding its cybersecurity practices, leading to significant losses during the specified class period from May 7, 2025, to December 16, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Coupang's inadequate cybersecurity allowed a former employee to access sensitive customer information for nearly six months without detection [3]. - As a result of the cybersecurity incident, Coupang's CEO resigned, which contributed to the decline in investor confidence and financial losses [3]. Group 2: Investor Information - Investors who purchased Coupang securities during the class period have until February 17, 2026, to seek appointment as lead plaintiff representatives [2]. - Interested investors can contact Berger Montague for more information regarding their rights and the lawsuit [4]. Group 3: Law Firm Background - Berger Montague is a prominent law firm specializing in complex civil litigation and class actions, with a history of recovering over $50 billion for clients [5]. - The firm has achieved more than $2.4 billion in post-trial judgments in 2025 alone, indicating its strong position in the legal field [5].